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PREFACE
This thesis submission contains an introduction, two chapters formatted as journal
articles, a discussion, recommendations for future work, and appendices containing studies that
did not fit within the article format used in Chapters 2 and 3. The bulk of the research narrative
is presented in article format in Chapter 2; this chapter will be submitted to Clinical Orthopedics
and Related Research or similar journal. Chapter 3 is a journal article titled
“Phosphatidylcholine Coatings Deliver Local Antimicrobials and Reduce Infection in a Murine
Model: A Preliminary Study.” The data in this article was first presented at the 2016
Musculoskeletal Infection Society conference in Charlotte, NC, and was later invited for
submission to the journal Clinical Orthopedics and Related Research. The article was accepted
after minor revisions and published in January 2017. Agarose overlay, cellular attachment
assay, and sterilization effects are covered in the Appendix. The Introduction (Chapter 1),
Evaluation of the In Vitro Efficacy of Phosphatidylcholine Coatings for Local Delivery of Cis-2Decenoic Acid and Antibiotics (Chapter 2), Discussion (Chapter 4), Conclusions (Chapter 5),
Recommendations for Future Work (Chapter 6), and Appendix are unique to this thesis.

iii

ABSTRACT
Harris, Michael, Anthony. M.S. The University of Memphis. August, 2017. Evaluation
of Phosphatidylcholine as a Local Drug Delivery Device for Application to Orthopedic Implants.
Major Professor: Dr. J. Amber Jennings, Ph.D.
Periprosthetic joint infection (PJI) is a major burden on the healthcare system and significantly
increases the mortality rate of patients following total joint arthroplasty. Prophylactic local
antibiotic delivery can reduce infection rates and improve patient outcome; however, infection
rates remain at 1-2%. Biofilm inhibitors are a possible means to prevent bacterial attachment to
implants. This work evaluates the use of a phosphatidylcholine coating for local delivery of
antibiotics and a biofilm inhibitor, cis-2-decenoic acid. Results show that antibiotic and biofilm
inhibitor are released at clinically relevant amounts for 5-9 days, indicating the phospholipid is a
viable carrier. In vitro studies suggest that the coatings are cytocompatible at relevant drug
loading concentrations, and a pilot in vivo model of PJI indicates that these coatings significantly
increase the rate of bacterial clearance in contaminated surgical wounds. Pending further
investigation, phosphatidylcholine may have clinical usefulness as a prophylactic drug delivery
coating on implants.
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CHAPTER 1
INTRODUCTION
Infection of orthopedic implants is a major healthcare concern, both in terms of cost and
patient morbidity. It is estimated that infected joint replacement and fracture fixation implants
cost approximately $1.8 billion in the United States alone in 2004 [14, 27], with hospitalization
costs reported to be 300% higher for infected joint arthroplasty patients [64]. Current rates of
infection are as high as 1-2% for primary joint arthroplasty, 5-40% for revision arthroplasty, and
20-30% for open fractures [14, 18, 56, 62]. There is some evidence suggesting that many
prosthesis failures diagnosed as aseptic loosening are actually caused by low grade biofilm
infections, which would further increase the reported rates of prosthesis infection [13, 50]. Joint
prosthesis infection can be devastating for the patients, who must typically undergo additional
hospitalizations, longer hospital stays, and multiple revision surgeries to eradicate periprosthetic
infection and/or remove the implant [64]. These patients are also subjected to increased physical
limitations, an overall decrease in quality of life, and up to a five-fold greater one year mortality
risk in comparison to non-infected surgical counterparts, with 25% of arthroplasty infection
patients dead within 5 years [4, 64, 70]. Given the increased number of elderly patients needing
joint replacements and rising life expectancy, the number of orthopedic implant procedures is
expected to continue rising [4, 62]. Reducing the incidence of orthopedic infection is therefore
essential to reducing healthcare costs, improving patient outcomes, and improving patient quality
of life.
Implants offer advantageous surfaces for biofilm growth due to heavy local vasculature
trauma at the time of implantation, decreased blood flow around the implant after healing, and
presence of a immune-incompetent fibro-inflammatory zone around the surface of the implant

1

that lowers the threshold number of pathogens required to induce infection [10, 53]. Bacterial
adhesins can attach to host proteins that adsorb onto the implant surface, and attachment is
further aided by favorable electrostatic interactions between the cell membrane and implant
surface [4, 14, 34, 62, 68]. This initial bacterial attachment is considered the critical point in the
establishment of biofilm implant infection [4, 68]. Once established, most biofilms are not
susceptible to systemic antibiotics [13]. Thus, due to the difficulty in treating biofilm infections,
preventative strategies are the most practical approach.
Once bacteria attach to an implant surface and form a biofilm, the only way to reliably
resolve the infection is to remove the implant and subject the patient to aggressive antimicrobial
therapy [13, 62]. The difficulty in treating these infections makes prevention key to reducing the
impact of orthopedic infection and improving patient outcomes. Surgical wound contamination
at the time of implantation is an ongoing concern, with recent studies finding bacterial
contamination of surgical gloves in 54-76% of orthopedic procedures [2, 16] and general sterile
field contaminations in 63% of surgeries [6]. Contamination rates as high as 90% have been
reported at “clean” implantation surgical sites at the time of closure [4, 53]. Retrospective
evaluations of total hip arthroplasty show that exogenous contamination at the time of surgery is
responsible for most acute and delayed infections, which account for approximately two thirds of
all hip arthroplasty infections [4, 21], and are defined as infections that present themselves within
3 months or between 3-24 months, respectively [69]. Up to one third of all infections can be
prevented by following infection prevention protocols, but hospital cost reductions limit staffing
and there is always some risk of infection from contamination by patient and surgeon skin [53].
Current standard of care treatment involves prophylactic administration of systemic
antibiotics immediately before the surgery, with surgical debridement, removal of implants, and
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additional systemic antibiotics if infection develops [62]. Prophylactic administration of
antibiotics 30-60 minutes before surgery can ensure inhibitory concentrations of antibiotic at the
implant site for about 3 hours [62]; however, local surgical trauma may prevent repeat doses of
antibiotic from effectively reaching the site. Local antibiotic delivery methods have been
investigated for several decades as a means of increasing antimicrobial concentration at the site
of the wound, while keeping systemic levels low, avoiding side effects associated with high
systemic levels, and allowing patients with previous antibiotic induced renal failure to be treated
[28, 34, 67]. Local application of vancomycin powder directly into the wound bed has become
popular in spinal surgery, with reported infections rates dropping from 2-12% to less than 1%
[60]. Despite its widespread use, there is little control over wound bed concentration, with
concentrations differing by as much as 10-20 fold in separate cases and reaching levels as high as
3000 µg/ml [61]. While vancomycin is not lethal to osteoblasts at this concentration,
vancomycin is less cytotoxic than most antibiotics and is poorly absorbed in wound beds [48,
61]. This method is therefore limited to vancomycin because other antibiotics are likely to be
absorbed faster or may cause cell damage at the high levels achieved in the wound bed.
Biomaterials can be used as local delivery devices that offer sustained, long-term drug
delivery profiles in contrast to repeated administration of drugs by other routes or rapid
absorption by direct application [7]. Antibiotic loaded polymethylmethacrylate (PMMA) cement
has been used for both prevention and treatment of periprosthetic joint infection, and can be
made into beads to insert into traumatic wounds. Animal models and retrospective clinical
studies have shown antibiotic delivery by PMMA, when used in conjunction with systemic
antibiotic therapy, can significantly reduce the risk of infection in orthopedic procedures [28, 33,
67]. Gentamicin loaded PMMA cement has been used successfully as a prophylactic antibiotic
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delivery device for decades [28, 34], but high doses of antibiotics weaken the cement and
findings of sub minimum inhibitory concentrations of gentamicin years after implantation have
raised concerns about generating antibiotic resistant bacterial strains [4, 34]. Several studies
have found that gentamicin loaded bone cement causes a significant increase in the recovery of
gentamicin-resistant bacteria from implants, likely as a result of long term sub-inhibitory elution
rates [34]. Sub inhibitory exposure may also encourage planktonic bacteria to form biofilm as a
defense mechanism [12]. Once elution rate drops, bacteria can even attach to the PMMA and
use it as a scaffold for biofilm formation [34].
Biodegradable delivery systems have been developed that offer similar drug elution
profiles but completely degrade over a specified time interval, including collagen fleece, calcium
sulfate, polymers such as poly-lactic acid, and chitosan [18, 67]. Unlike PMMA cement, the
elution profile and degradation rate of the carrier matrix can be modified to increase elution rate
or duration, and there is no need for follow up surgery to remove the device. A general concern
with many of these systems, however, is that drug elution often outpaces degradation, leaving an
empty scaffold near the implant site [18, 20]. Degradation products may also decrease
surrounding cell viability or elicit an immune response. Purified calcium sulfate has been shown
to cause an inflammatory reaction with large amounts of sterile serous drainage in some patients
that may necessitate removal of the device [37, 51]; however, this is not typically observed with
unpurified plaster of Paris. Similar reactions have been noted in patients with poly lactic acid or
poly glycolic acid implants, limiting their use as drug delivery devices [5, 11].
Coatings may be advantageous to other delivery systems in that the entire surface is
protected at the time of implantation, whereas other methods such as beads or sponges rely on
diffusion to achieve effective levels of antibiotic around the implant. Many of these delivery

4

systems have been used to form a drug loaded coating around the implant surface, including
poly-lactic acid [22, 65], polymethylmethacrylate [65], chitosan [23], and calcium sulfate [63],
for delivery of antibiotics such as gentamycin. Vancomycin has been covalently bound to
titanium implants via a series of linker molecules to form a coating of vancomycin that can
significantly reduce biofilm formation in vitro and during in vivo animal models of orthopedic
infection [3, 58]. The presence of a permanent, covalently bound antibiotic coating is desirable
for several reasons in that it would provide long-term protection against hematogenously spread
bacteria, the entire implant surface would be protected from the time of implantation, and the
implant would not release any of the antibiotic, reducing the risk of developing antibiotic
resistant bacteria. However, there are also several important limitations. After in vivo testing, it
was found that the vancomycin had been removed from many places on the implant surface [58].
Since the coating does not elute antibiotics, any exposed areas on the metal surface are
vulnerable to bacterial attachment. Second, the vancomycin used in these studies is not a broad
spectrum antibiotic, leaving the implant susceptible to gram negative bacteria. Also, the
technique will be limited based on the availability of binding sites on the antibiotic and suitable
linker molecules. Sol-gel coatings of silica containing vancomycin have also been reported to
elute vancomycin in vitro and reduce bacterial infection in vivo; however, were not able to
completely clear bacteria in a rat model of orthopedic infection and had to be pre-fabricated
before the surgery [1].
Phosphatidylcholine (PtC) is a natural occurring phospholipid that has been used as a
drug delivery coating with some success in preliminary in vitro studies (Fig. 1), and is currently
used in some demineralized bone matrix products to improve bone ingrowth [29]. PMMA is
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limited in antibiotic choice due to the high reaction
temperatures generated during fabrication [28], while PtC
can be loaded with any antibiotic powder by hand mixing
and applied to implants by gently wiping it across the
surface. Since the coating is applied directly to the implant
surface, it will provide increased protection compared to
other local delivery forms such as beads, spacers and sponges, which rely on diffusion and are
often unable to achieve high antimicrobial concentrations around the entire implant [45, 59].
The coating also degrades during the healing process [25], unlike nondegradable PMMA beads,
which require a separate procedure for removal. The rapidly degrading nature of PtC precludes
concerns about sustained low level drug release or late stage attachment of hematogenous
bacteria. In a rabbit based model of periprosthetic joint infection by Jennings et al., vancomycinloaded phosphatidylcholine coatings on wire implants significantly reduced the amount of viable
bacteria recovered from the implant after 7 days (Table 1, Table 2) [31]. However, viable
bacteria capable of rebounding and causing infection were recovered from 3/5 treated rabbits.
Potential advantages and limitations of PtC coatings for drug delivery are listed in Table 3.
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Table 3. Advantages and limitations of PtC coatings
Advantages
•
•
•
•
•
•

Limitations
•

Biodegradable
Full implant coverage
Protection begins prior to surgery
Easily loaded with multiple drugs
PtC is used clinically with no reported
adverse side effects
No harsh fabrication steps or
chemicals

•
•
•

Must be applied to implant during
surgery
Thin coatings do not contain as much
antibiotic as large depot based
delivery systems
May affect cellular attachment and
healing
Coating may be removed during
handling

The majority of implant-associated infection is caused by biofilm, a colony of many
bacteria that forms when planktonic bacteria adhere to the surface, begin secreting a
polysaccharide and protein extracellular matrix, and multiply [12, 14, 62]. Once in the biofilm
state of growth, bacterial cells are protected from immune cell attack and are up to thousands of
times more resistant to antibiotics [4, 57, 62]. The bacterial cells lose this resistance if released
from the biofilm, suggesting that the resistance is a phenotypic phenomenon and not the result of
plasmids or other genetic modifications. Proposed explanations for the antibiotic resistance of
biofilms include diffusional constraints within the biofilm matrix, deactivation of antibiotics at
the biofilm surface, local pH increases at the biofilm core that reduce antibiotic effectiveness,
slower growth rate, and the presence of persister cells [14, 34, 41, 57]. Persister cells are a small
subset of bacterial cells ( < 1%) that enter a nonproliferative, nonmetabolic state during slow or
stationary growth phases, such as in maturing biofilm. This metabolic dormancy makes them
much less susceptible to antimicrobials, which cannot corrupt the target molecules when they are
not being used by the cell [38]. In the event of wide spread cell death, such as after treatment
with large doses of antibiotics, these persister cells can re-enter the proliferative cycle and
repopulate the biofilm [38, 39]. While biofilm and persister states of growth are phenotypic, it
7

should be noted that biofilm structure is highly conducive to horizontal gene transfer, and genetic
antibiotic resistance can quickly spread if present in the bacterial community [10, 40]. S. aureus
and P. aeruginosa are responsible for most Gram-positive and Gram-negative biofilm based
periprosthetic joint infections, respectively, with Gram-positive bacterial infections being more
common [4, 56].
The rise of multi-drug resistant bacterial strains has caused concern about the widespread
use of antibiotics and led to the search for new classes of antibiotics or non-antibiotic based
infection prevention strategies [8, 19, 55]. Naturally occurring biofilm dispersal agents have
gained attention due to their ability to revert biofilm communities back into the planktonic state,
eliminating the antimicrobial tolerance conferred by the biofilm [30, 41, 42, 52]. These
inhibitors are typically quorum sensing molecules produced by mature biofilms to induce
dispersion of sessile bacteria, which keeps the biofilm population in check and allows dispersed
bacteria to populate another site [35]. Among the recently investigated dispersal agents, cis-2decenoic acid (C2DA) has shown potential due to its cross species and cross kingdom activity,
effectiveness at low concentrations, good cytocompatibility, synergistic activity with many
antibiotics, and its ability to inhibit biofilm formation when added to planktonic bacteria [15, 32,
41-43, 49, 54].
C2DA (Fig. 2) is a short chain fatty acid chemical messenger isolated from P.
aeruginosa biofilms with broad spectrum biofilm dispersal capabilities, which is accomplished
by inducing changes in gene transcription at nanomolar concentrations. Microarray analysis
shows that C2DA modulates the expression of 666 genes in P. aeruginosa, most of which are
involved in metabolism, proliferation and virulence, suggesting that C2DA signals increased
metabolic activity [46]. Addition of C2DA to biofilm cultures will significantly increase the
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number of planktonic cells released into the surrounding medium, but will also vastly reduce the
surface area occupied by the biofilm [32, 46, 47]. In addition to causing bacterial dispersion,
C2DA can inhibit the formation of biofilm when added to planktonic populations of bacteria, and
reverts persister cells in P. aeruginosa and E. coli biofilms back into a metabolically active state
[42]. C2DA has been shown to induce biofilm dispersion in multiple bacterial and at least one
fungal species, including E. coli, K. pneumoniae, P. mirabilis, S. pyogenes, B. subtilis, S. aureus
and C. albicians [15]. It is hypothesized that Pseudomonas evolved the ability to induce
dispersion of various bacteria and fungi as a means of regulating healthy polymicrobial biofilms.
We have previously shown that C2DA is bactericidal at high concentrations (500 µg/ml)
and can act synergistically with certain antibiotics, including tetracycline, amikacin, ceftazidime,
linezolid, and ciprofloxacin [32, 43]. These effects are not seen at the low nM concentrations
capable of inducing genetic effects [47, 54], suggesting that the bactericidal and synergistic
activity results from a separate mechanism. The mechanism of this synergistic activity is likely
the result of increased membrane permeability, with high concentrations disrupting the Grampositive S. aureus membrane to the point of suspected rupture [43]. This is in accordance with
previous research confirming the antibacterial properties of free fatty acids, particularly short
chain fatty acids with cis conformation double bonds including C2DA [17]. It is hypothesized
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that the amphipathic structure of free fatty acids allows them to interact with bacterial cell
membranes, and a cis conformation double bond will produce a bend in the carbon chain that
opens pores and increases fluidity within the membrane [17]. This increased membrane
permeability allows antibiotics to enter the cell at an accelerated rate, causing synergistic effects
with antibiotics that act within the cell and additive effects with antibiotics that act at the cell
membrane [43]. The degree of synergism can be quantified using the fractional inhibitory
concentration index (FICI), which compares the minimum biofilm inhibitory concentration
(MBIC) of each drug lone with the MBIC when they are
combined (Equation 1, Fig. 3). FICI values below 1
indicates a synergistic response between drugs, and values
1-2 indicate additive effects. Similar studies with
polymyxin B, a known membrane permeabilization agent,
have found synergism with internal acting antibiotics using
this same mechanism [66].

Equation 1. FICI=

MBIC C2DA in combination MBIC antibiotic in combination
+
MBIC C2DA alone
MBIC antibiotic alone

Additional biofilm inhibitors have been investigated. D-amino acids have been shown to
induce biofilm dispersion and increase the effectiveness of some antibiotics against biofilm, but
do not have significant bactericidal activity on their own [52]. Farnesol is another natural
quorum sensing molecule that induces biofilm dispersal, has combinatorial effects with
antibiotics, and has bactericidal activity against planktonic bacteria, but is cytotoxic to
osteoblast-like cells at concentrations required to induce dispersion [9, 30, 49]. Of the biofilm
inhibitors studied, C2DA is advantageous because of its cytocompatibility at effective levels,
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synergistic activity with antibiotics, ability to revert persister cells to an antimicrobial susceptible
state, and broad spectrum activity.

Hypothesis:
C2DA may be able to prevent or delay bacterial attachment to an implant surface,
allowing antimicrobials to kill bacteria before they form biofilm. Local delivery of C2DA and
antimicrobials from an implant surface would therefore protect the implant from bacterial
contamination occurring at the time of surgery. We hypothesize that phosphatidylcholine can
release active concentrations of antibiotics and cis-2-decenoic acid for a clinically relevant time
period of 1 week without inducing cytotoxic effects in in vitro studies and a preliminary in vivo
model of periprosthetic joint infection.
Research Objectives:
The aim of this study is to develop PtC coatings loaded with combinations of C2DA and
antimicrobials that can prevent orthopedic infection on implant surfaces for several days post
implantation. Specific research objectives (Fig. 4):
1. Determine the in vitro elution characteristics of amikacin, tetracycline,
ceftazidime, vancomycin, ciprofloxacin and C2DA from PtC coatings, with the
goal of maintaining above MIC elution concentrations for 1 week.
2. Demonstrate in vitro antibacterial properties of eluate samples against
Staphylococcus aureus and Pseudomonas aeruginosa.
3. Demonstrate in vitro cytocompatibility PtC coatings containing antibiotics and
C2DA using cellular proliferation, agarose overlay and cellular attachment assays
using MC3T3 osteoblasts and comparing to ISO 10993-5 guide lines.
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4. Evaluate the in vivo potential of PtC coatings using a murine model of orthopedic
infection.
5. Determine the effects of low dose gamma sterilization on PtC elution
characteristics and C2DA structural integrity.
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CHAPTER 2
Evaluation of the In Vitro Efficacy of Phosphatidylcholine Coatings for Local
Delivery of Cis-2-Decenoic Acid and Antibiotics
Introduction:
Periprosthetic joint infections (PJI) occur in approximately 1-2% of primary joint
arthroplasty and 5-40% of revision arthroplasty, placing patients at a 5 times greater one year
mortality risk and costing the US a projected $1.6 billion by 2020 [20, 37]. Most of these
infections are caused by biofilm based bacteria, attached communities of bacteria that are incased
by extracellular matrix and protected from both immune cell attack and antibiotics [5, 34].
Biofilm inhibitors, such as cis-2-decenoic acid (C2DA), have been shown to disperse cells from
mature biofilms, returning them to the more susceptible planktonic form, and inhibit the
formation of new biofilms in cultures of planktonic bacteria [18, 22, 23]. Local delivery of these
biofilm inhibitors may prevent bacterial attachment to implant surfaces, thereby leaving it into a
susceptible form that can be more easily treated with antibiotics. Among biofilm inhibitors,
C2DA has potential advantages due to cross species and cross kingdom activity,
cytocompatibility at concentrations up to 500 µg/ml, and synergistic activity with common
antibiotics [15, 22-24, 31]. C2DA is a hydrophobic short chain fatty acid, making dual delivery
with water soluble antibiotics challenging. The amphipathic nature of the phospholipid
phosphatidylcholine (PtC) makes it an appropriate delivery system for both.
Previous work in our lab has shown that application of phosphatidylcholine (PtC) loaded
with 5% amikacin and/or 10% C2DA was sufficient to significantly increase the rate bacterial
clearance in a pilot in vivo murine model of PJI; however, in vitro elution studies showed that
amikacin release had essentially stopped by day 3 [13]. It has been well established that choice
13

of antibiotic has a significant impact on the elution profiles of antibiotics from
polymethylmethacrylate bone cement, with aminoglycosides eluting in significantly higher
amounts other antibiotics such as vancomycin, neomycin, tetracycline and ceftazidime [21, 28,
35]. Similar effects have been seen with calcium sulfate, with gentamicin and clindamycin
eluting at significantly higher rates than vancomycin and teicoplanin over the first 24 hours [36].
However, unlike non-degradable PMMA, this rapid initial release caused gentamicin and
clindamycin to elute at lower concentrations at later time points in the study. In a study on
antibiotic release on chitosan films, approximately 85% of loaded amikacin was released within
the first hour while only 30% of daptomycin from similar coatings was released over this time
[27]. These studies suggest that antibiotic choice may significantly alter the elution and
antibacterial characteristics of PtC coatings as well, further improving clinical potential.
Therefore we asked: (1) Will choice of antibiotic significantly affect the elution rate of
antibiotic and C2DA from phosphatidylcholine coatings in in vitro elution studies? (2) Will
choice of antibiotic affect the duration of antibacterial and antibiofilm activity from coating
eluates? (3) Are phosphatidylcholine coatings cytocompatible with MC-3T3 osteoblasts when
loaded with physiologically relevant doses of antibiotic and C2DA?
Materials and Methods:
Antibiotic and C2DA elution profiles were determined using in vitro elution studies.
These elution samples were then used in bacterial turbidity and biofilm studies as a qualitative
assessment of antibacterial activity. A direct cell viability assay was then used to quantitatively
assess in vitro cytocompatibility of the coatings.
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Fabrication:
Vancomycin and ceftazidime were purchased from Sigma Aldrich (St. Louis, MO, USA).
Levofloxacin and ciprofloxacin were purchased from Alfa Aesar (Haverhill, MA, USA).
Amikacin and tetracycline were purchased from MP Biomedicals (Santa Ana, CA, USA). C2DA
and the appropriate antibiotics were mixed with 90 g Phospholipon ® (Lipoid, Ludwigshafen,
Germany) by mixing 0 g, 50 mg, or 150 mg C2DA and 0 g, 50 mg, or 150 mg antibiotic with
enough PtC to achieve a total mass of 1 g. Each group was mixed under aseptic conditions by
hand until the antibiotic and C2DA appeared homogeneously distributed. These mixtures were
stored at -8° C until use.
Elution:
Commercially pure (cp) titanium coupons (1 cm diameter x 2 mm thickness) were wet
polished using a succession of 400, 800 and 1200 grit sandpaper, sonicated in acetone and
autoclaved at 121° C for 30 minutes. PtC mixtures containing C2DA alone or ciprofloxacin,
amikacin, tetracycline, ceftazidime, or vancomycin with and without C2DA was warmed to
room temperature and applied to the titanium coupons (n=4) by gently wiping the mixture across
the coupon surface to leave a thin coating, with coupon mass measured before and after coating.
Coupons were placed in 24 well plates, with each well lined with a 41 µm nylon filter (Merck
Millipore, Billerica, MA, USA). One mL of phosphate buffer saline (PBS) was added to each
well and the plates were placed on an orbital shaker at 37°C. Samples were taken with complete
media refreshment every 24 hours for 7 days. Based on preliminary results, the elution study
was carried out an additional 2 days for coatings loaded with ciprofloxacin. Antibiotic and
C2DA concentration in each sample was determined using HPLC (Dionex Ultimate 3000,
Thermo Scientific, Waltham, MA, USA).
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Turbidity and Biofilm Assay:
PtC eluate activity was assessed using a bacterial turbidity and biofilm assay. Separate
Staphylococcus aureus (UAMS-1) and Pseudomonas aeruginosa (PA-ATCC 27317) cultures
were grown overnight in trypic soy broth (TSB) and diluted 1 in 200. Using aseptic technique
and sterile supplies, 15 µL of each eluate sample was added to 96 well plates and then inoculated
with 135 µL of either UAMS-1 or PA-ATCC 27317, giving a final sample dilution of 1:10.
Background absorbance of the microplates was measured before use at 540 nm (ELx800, Biotek,
Winooski, VT, USA). The top row of each plate contained six inoculated negative controls and
six uninoculated positive controls. The plates were incubated overnight, after which sample
turbidity was measured as absorbance at 540 nm. Each plate was also examined visually to
determine which samples were turbid, indicating bacterial growth in the presence of the eluate
sample. Plates were then washed three times with deionized water to remove planktonic bacteria
and the remaining biofilm was stained using 2% crystal violet. Each plate was heavily rinsed
with water to remove excess crystal violet, then a destain solution containing 10% methanol and
7.5% acetic acid was added to each well to extract the stain taken up by the biofilm. Absorbance
at 540 nm was then used to quantify biofilm formation [9, 25].
Quantitative Viability Assay:
MC-3T3 osteoblasts were grown in Dulbecco's Modified Eagle Medium w/ High Glucose
supplemented with 10% Fetal Bovine Serum and 100 µg/mL Normocin™ antimicrobial reagent
(InvivoGen, San Diego, CA). One cm titanium coupons were wet polished using a succession of
400, 800 and 1200 grit sandpaper, sonicated in acetone and autoclaved at 121° C for 30 minutes.
Using aseptic technique, PtC mixtures were used to coat the titanium coupons (n=3), which were
then placed in 24 well plates and seeded with 1*104 cells/cm2. Media was exchanged daily for
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24 hours. Uncoated titanium coupons were used as controls. At t=24 h and t=72 h, CellTiterGlo® (Promega, Madison, WI) was added to 3 samples per group and luminescence was
measured (ELx800, Biotek, Winooski, VT, USA). The luminescence measurements were
normalized to those from the uncoated controls as a measure of cell viability.
Statistical Analysis:
Two way ANOVA with Holms-Sidak post hoc was used to test for differences in coating
mass among groups with and without C2DA, as well as testing for differences in elution profiles.
One way ANOVA with Holm-Sidak post hoc was used to test for significant differences in cell
viability at each time point. A level of significance α = 0.05 was used for all studies. All
statistical testing was performed using SigmaPlot (Systat Software, Inc, San Jose, CA, USA).
Results:
Elution:
There was a 36% reduction in applied coating mass between coatings that contained 15%
antibiotic alone and those that contained both 15% antibiotic and 15% C2DA (p < 0.001).
Among PtC coatings containing only C2DA, mass of the applied coatings with 15% wt. C2DA
was approximately double that of the 10% and 5% C2DA coatings (p= 0.05). Coatings with
15% C2DA eluted significantly more C2DA than coatings with 5% or 10% C2DA (p < 0.01),
and elution gradually tapers to 5 µg/ml on day 7 (Fig. 5). Elution rates for coatings with 5%
C2DA or 10% C2DA dropped below 5 µg/ml by day 4 and 5, respectively. Ceftazidime,
tetracycline, vancomycin and amikacin release in a biphasic pattern, with a burst release of over
200 µg/ml during the first 1-2 days that tapers off below 20 µg/ml by day 4 (Fig. 6).
Ciprofloxacin release from coatings with 15% ciprofloxacin, 15% C2DA remains relatively
steady between 25-100 µg/ml throughout the extended 9 day elution study. Comparing coatings
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with various concentrations of ciprofloxacin, elution is similar between groups until after day 6,
when coatings 5% or 10% ciprofloxacin elute significantly less antibiotic than those loaded with
15% ciprofloxacin (p < 0.05, Fig. 7).
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Turbidity and Biofilm Formation:
Results of the turbidity testing are presented in Tables 4 and 5, with a minus sign
indicating that all samples in a group were inhibitory at that time point, and each plus sign
indicating bacterial growth in a sample. The eluate samples from coatings loaded with 15%
ciprofloxacin and 15% C2DA were able to inhibit both S. aureus and P. aeruginosa formation
throughout the 9 day study (Table 4 and 5). Eluate samples from the rest of the ciprofloxacin
loaded coatings were inhibitory at most time points. Coatings loaded with tetracycline
performed well against S. aureus, remaining inhibitory for 3-7 days, although they only inhibited
P. aeruginosa growth for 1-2 days. The remaining antibiotic coatings were unable to inhibit
either strain for the full 7 days.
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Eluate samples from coatings loaded with C2DA alone were able to reduce P. aeruginosa
biofilm formation by approximately 40-60% compared to controls, however had less biofilminhibitory effect on S. aureus formation after day 2 (Table 6 and 7). Coatings loaded with
tetracycline were inhibitory against S. aureus biofilm throughout the 7 day elution study and
reduced P. aeruginosa biofilm formation by over 50% at most time points. Vancomycin loaded
coatings performed very well against S. aureus biofilm for 5-6 days. Ceftazidime and C2DA
loaded coatings were effective against P. aeruginosa for the first 4 days but were largely
ineffective against S. aureus after day 2. Coatings loaded with ciprofloxacin were again the most
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effective in this study, with 15% ciprofloxacin 15% C2DA coatings causing near complete
inhibition of biofilm by both strains throughout its extended 9 day elution study.

Cytocompatibility:
The PtC coating without antibiotics caused no significant change in osteoblast cellular
viability compared to the uncoated titanium control at either time point (p > 0.5, Fig. 8). For
drug loaded coatings, cellular viability at the day 1 time point ranged from 58% for PtC with
15% ceftazidime, 15% C2DA to 76% for coatings loaded with only 15% C2DA. The decrease in
viability for drug loaded coatings was significant by ANOVA (p = 0.042), but Holm-Sidak post
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hoc was unable to isolate any one group that was significantly different from the uncoated
control (p > 0.08). The day 3 viability for groups loaded with 10% C2DA, 15% C2DA or 15%
ceftazidime and 15% C2DA increased compared to day 1 to greater than 80% that of the
controls. The remaining groups had a viability between 50-69%, with the 15% amikacin, 15%
C2DA coating, 15% tetracycline, 15% C2DA coating, and 15% vancomycin, 15% C2DA coating
all causing statistically significant reductions in viability (p = 0.009, p = 0.016, p = 0.049,
respectively).
Discussion:
Local antibiotic delivery using PMMA has been shown to effectively reduce the rate of
orthopedic infection in joint arthroplasty procedures for several decades, although growing
concerns about extended release of sub-MIC levels of antibiotic have called its use into question
[3]. When used for prophylaxis in primary total joint arthroplasty, PMMA is typically loaded
with only 0.5-1 g gentamicin or tobramycin to maintain the mechanical properties of the cement
[12, 17]. While the exact release kinetics of antibiotics from PMMA is debated, multiple studies
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suggest that low-dose aminoglycoside loaded PMMA cement elutes most of its released
antibiotics during the first 24 hours, and elution drops below effective levels between day 2 [26,
32] and up to 10 days [7]. PtC is advantageous as a carrier system in that it rapidly degrades,
precluding concerns about extended low level elution, and can be applied to the entire implant,
as opposed to just the implant-bone interface, offering increased protection. The elution and
bacterial assays of this study suggest that PtC coatings can release active concentrations of both
antibiotics and the biofilm inhibitor C2DA for similar time periods compared to low dose
PMMA. C2DA has been previously shown to both disperse biofilm-based bacteria and inhibit
biofilm formation [6, 22], suggesting that locally delivered C2DA can not only increase the
effectiveness of antibiotics but also prevent bacterial attachment to the implant surface. This
preliminary study suggests that C2DA and antibiotic loaded PtC may be a viable alternative to
low dose PMMA as a prophylactic measure against PJI.
While the PtC coatings show promise, there are some limitations to this study. The in
vitro elution study is not fully representative of the conditions and processes occurring in vivo,
which may affect PtC degradation. Previous studies have also suggested that daily media
refreshment may create an artificially high diffusion gradient, increasing the rate of elution seen
in vitro [19]. This may prove advantageous in vivo, as a lowered elution rate would effectively
extend the duration of duration of active antibiotic release. The in vitro turbidity and biofilm
assays were also completed using static microplate assays which ignore the role of shear forces
and immunological factors that are present in vivo, as well as various factors and compounds
found in vivo that are left out of standard bacterial media [4, 8]. As such, the results of these
studies should only be used for screening the relative effectiveness of each antibiotic as delivered
by C2DA, and not as a reflection of the actual effectiveness of the C2DA to inhibit biofilm
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formation on an implant surface. Previous studies have already firmly established the ability of
C2DA to reduce and/or inhibit biofilm formation, and the effects of C2DA in the coating will
need to be determined in future studies featuring more robust shear flow bioreactor setups or in
vivo models.
The extended duration and limited burst of ciprofloxacin release may be in part due to the
limited solubility of ciprofloxacin at physiologic pH, slowing its release into the PBS [1]. Oddly,
several groups loaded with ciprofloxacin exhibited a sharp drop in elution on day 6 that
recovered by day 7. The reason for this temporary drop in elution is unclear but may be related
to the rate of hydrolysis within the phosphatidylcholine [11]. The steady, extended elution
pattern of ciprofloxacin is favorable compared to the burst response seen with the other
antibiotics; however, rising fluoroquinolone resistance and the association between their use and
methicillin resistant S. aureus (MRSA) has called their use into question [10]. The antibiotics
loaded into PtC coatings would not be delivered in sufficient quantities to raise systemic levels
significantly, thus limiting the likelihood of increasing the prevalence of resistant bacteria.
Many healthcare systems require MRSA screening prior to admitting patients, allowing surgeons
to choose more effective antibiotics on patients carrying these highly resistant strains.
Vancomycin and tetracycline are still being released by day 7, indicating that they may be
suitable alternatives. The fact that these coatings can be mixed immediately before surgery, as
opposed to prepackaged, allows a wider clinician choice of antibiotic to help combat patient or
hospital specific concerns.
The extended elution and antibacterial activity against both gram positive and gram
negative bacteria are major advantages of the 15% ciprofloxacin, 15% C2DA coatings.
Previous studies have shown that C2DA works well with ciprofloxacin to kill mature biofilms
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[29]. The limited antibacterial effects of levofloxacin coatings after day 4, compared to similar
fluoroquinolone ciprofloxacin, can be explained by the burst response of levofloxacin seen in the
elution study, further confirming prolonged release of ciprofloxacin. Broad spectrum antibiotics
tetracycline and amikacin were able to inhibit growth of both strains for several days, with
tetracycline performing better against S. aureus and amikacin performing better against P.
aeruginosa. Given that the most commonly delivered antibiotics from PMMA are
aminoglycosides and their well-established history of reducing PJI when delivered locally,
amikacin would be an acceptable choice; however, care must be taken during revision surgeries,
as previous use of antibiotic loaded bone cement can generate aminoglycoside resistant bacteria
[16].
Cell viability and proliferation studies indicate that phosphatidylcholine coatings without
antimicrobials have little to no effect on osteoblast proliferation. This is in accordance with a
previous rabbit model of orthopedic implant infection performed by our lab, in which little
inflammation was found on histology slides of tissue adjacent to titanium wires coated with
vancomycin loaded phosphatidylcholine [14]. While there was a nonsignificant drop in
proliferation over day 1, groups with 10% or 15% C2DA recovered by the third day. The high
C2DA elution concentrations seen over the first 24 hours may slow proliferation; however,
proliferation appears to return to normal after elution levels drop by day 2-3 as was seen in
previous studies [15, 31]. All coatings loaded with antibiotics and C2DA had reductions greater
than the 30% cutoff listed by ISO 10993-5 standards for cytocompatibility, likely due to the
known cellular effects of high doses of antibiotics and biofilm inhibitors seen during the first 24
hours of elution. As a qualitative note on cellular response to the coatings, cells from all samples
exhibited normal morphology under visual inspection at 20x magnification and continued to
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proliferate throughout the study. Lowering the drug loading concentration would likely improve
cellular proliferation to more acceptable levels given that the PtC coating itself shows no signs of
disrupting cell growth. However, C2DA has been shown to be cytocompatible with fibroblasts
and osteoblasts at concentrations up to 500 µg/ml [15, 31], and antibiotics reduce cellular
proliferation and/or cause cell death at varying concentrations from as low as 100 µg/ml for
ciprofloxacin to as high as 2000 µg/ml for vancomycin [2, 30]. Antibiotic concentrations above
cytotoxic levels have been reported from various drug delivery systems, including high dose
PMMA and direct application of vancomycin powder, without adverse clinical side effects [28,
33], indicating that the present loading concentrations may still be acceptable for in vivo use.
In conclusion, PtC coatings are capable of delivering active concentrations of antibiotics
and C2DA for up to 9 days. The inclusion of the biofilm inhibitor may further increase coating
effectiveness in vivo by preventing initial bacterial attachment to the implant surface; however,
future in vitro and in vivo models of biofilm formation will be required to optimize C2DA
loading concentration and further justify its use. Future studies will also examine advanced
coating delivery techniques that will both increase the consistency of coatings and the speed of
the coating process, thereby improving clinical applicability.
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CHAPTER 3
Phosphatidylcholine Coatings Deliver Local Antimicrobials and Reduce Infection in a
Murine Model: A Preliminary Study
Introduction
Bacteria in biofilm based implant infections are up to 1000x more resistant to
antimicrobials than their planktonic counterparts, making systemic antibiotic therapy ineffective
in the treatment of periprosthetic joint infection (PJI) [3]. Local antibiotic delivery methods have
been investigated for several decades as a means of increasing antimicrobial concentration at the
site of the wound while keeping systemic levels low, avoiding potential side effects. Antibioticloaded polymethylmethacrylate (PMMA) cement has been used for both prevention and
treatment of PJI, and has been shown to reduce the risk of infection in orthopaedic procedures [9,
15, 29] . The primary disadvantage of PMMA is that it is not biodegradable, so a second
procedure is often required to remove the device. Biodegradable delivery systems have been
developed that offer similar drug elution profiles but completely degrade over a specified time
interval, including collagen fleece, calcium sulfate, polymers such as lactic acid, and chitosan [5,
29]. The phospholipid phosphatidylcholine (PC) has been used in both purified form and as a
PC-sesame oil gel to deliver antibiotics with favorable reductions in bacterial colony forming
units (CFUs) during in vivo PJI models [13, 19]. PC has already been approved by the FDA as
an additive to demineralized bone matrix to enhance bone ingrowth, suggesting that it would not
induce adverse effects when used for drug delivery applications.
Naturally occurring biofilm dispersal agents have gained attention as a result of their
ability to revert biofilm communities back into the planktonic state, eliminating the antimicrobial
tolerance conferred by the biofilm [11, 16, 17, 24]. Among the recently investigated dispersal
agents, cis-2-decenoic acid (C2DA) has shown potential as a result of its cross-species and cross-
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kingdom activity, effectiveness at low concentrations, good cytocompatibility, synergistic
activity with many antibiotics, and its ability to inhibit biofilm formation when added to
planktonic bacteria [4, 14, 16-18, 23, 25]. Despite promising results, there is currently a research
gap between in vitro studies and development of effective local delivery devices for in vivo use.
There is also a lack of in vivo studies examining the anti-biofilm efficacy of C2DA at surgical
wounds, or confirming in vivo synergistic responses to antibiotics. The amphipathic structure of
PC may make it an ideal carrier of both a hydrophobic fatty acid like C2DA and water soluble
antibiotics. PC has been previously used to deliver amikacin [13], which exhibits synergistic
activity with C2DA in vitro [18] and has been shown to be cytocompatible with osteoblasts at
concentrations up to 2000 µg/ml [22].
Therefore, we asked: (1) What are the in vitro elution profiles of amikacin and C2DA
from phosphatidylcholine-coated coupons in incubated phosphate buffered saline? (2) Does the
presence of C2DA lower the amount of amikacin required for bacterial inhibition in overnight
bacterial turbidity assays? (3) Does addition of amikacin and C2DA result in decreased colonyforming units on wire and bone when compared with phosphatidylcholine coatings alone in a
mouse model of PJI?
Materials and Methods
Elution of antibiotics was first evaluated using in vitro elution studies. Antimicrobial
activity was confirmed by turbidity testing using the eluate samples. Coating efficiency then was
tested in vivo using a murine model of PJI.
Fabrication
C2DA and amikacin (MP Biomedical, Santa Ana, CA, USA) were incorporated into 90 g
Phospholipon (Lipoid, Ludwigshafen, Germany) by mixing 0g, 50 mg, 150 mg, or 250 mg
31

C2DA and 0g, 50mg, 150 mg, or 250 mg amikacin with enough PC to achieve a total mass of 1
gram [12]. Individual coatings were mixed at room temperature through a chopping and
kneading process until the drug payload was homogeneously distributed throughout the PC.
Drug-loaded PC mixtures were made 24 hours before study use and stored at -8° C.
Elution and Activity
In vitro drug elution studies were performed to determine the effects of drug loading
levels on release profile before in vivo experiments. Six-well plate CellCrownTM inserts
(Scaffdex, Tampere, Finland) were fitted with 41-µM nylon filters and inserted into six-well
plates. Three-quarter inch titanium coupons were cut in house, polished by successive wet
grinding with 400, 800 and 1000 grit sandpaper, sonicated in acetone for 30 minutes and
autoclaved for 30 minutes at 121° C. Each coupon was coated by dragging the
phosphatidylcholine mixture across the implant surface under gentle pressure to leave a thin
coating (n=4 per group). Each coupon was inserted into a separate CellCrownTM fitted well and
each well received 3 mL phosphate-buffered saline (PBS). An adhesive cover was applied to
each well plate and each plate was wrapped heavily with parafilm. The plates were placed in a
37° C incubator on a Belly DancerTM shaker (IBI Scientific, Peota, Iowa). Samples were taken
every 24 hours with complete media refreshment for 7 days.
Amikacin and C2DA concentration in the eluate samples were measured using highperformance liquid chromatography (Thermo Scientific Dionex UltiMate® 3000, Waltham, MA,
USA) with a C18 column (Thermo Scientific BDS HypersilTM C18 150 x 4.6 mm, particle size 5
µm). C2DA was measured at 209 nm using an isocratic buffer of 50.4% acetonitrile, 21.6%
tetrahydrofuran, and 28.1% of 1% phosphoric acid [6]. Amikacin concentration was determined
using a charged aerosol detector (Dionex Corona Veo Charged Aerosol Detector RS; Thermo
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Scientific) with an isocratic buffer of 98% 55 mM trifluoracetic acid, 1% acetonitrile, and 1%
methanol [28].
PC eluate activity was determined using a turbidity growth inhibition assay.
Staphylococcus aureus (UAMS-1) and Pseudomonas aeruginosa (PA-ATCC 27317) were
grown overnight in tryptic soy broth (TSB). UAMS-1 was diluted 1:50 and PA-ATCC 27317
was diluted 1:200. Representative samples from each elution group were selected for turbidity
testing. In a 96-well plate, each well received 130 µL TSB, 20 µL of the appropriate eluate
sample, and 50 µL of bacterial inoculum (a 1:10 final dilution for each eluate sample). Each
sample was tested against UAMS-1 and PA-ATCC 27317 in triplicate. The top row of each plate
contained controls with 6 inoculated (negative controls) and six uninoculated (positive controls)
wells receiving PBS instead of the eluate sample. The plates were incubated overnight at 37° C
and then turbidity was measured as absorbance at 540 nm (ELx800; Biotek, Winooski, VT,
USA). The cutoff value for growth inhibition was set at 10% of the difference between positive
and negative controls, plain TSB and inoculated TSB without antimicrobials, respectfully.
In Vivo Efficacy
In vivo efficacy was tested using a pilot murine study at the University of Arkansas for
Medical Sciences. PC was sterilized by gamma radiation, C2DA was filter-sterilized with a
0.20-µm syringe tip filter, and powdered amikacin was sterilized by brief exposure to UV light.
Implant wires were autoclave-sterilized at 121° C before use. PC mixtures with no
antimicrobials, 5% wt amikacin, 10% wt C2DA, or 5% wt amikacin and 10% wt C2DA were
made using an aseptic technique 24 hours before the surgery and stored at -8° C.
Eight to twelve week old C57BL/6 mice weighing 16-18 grams were anesthetized with
isoflurane and Avertin (0.4-0.6 mg/g). A small incision was made over the left knee and a hole
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was bored into the left distal femur using 26-gauge and then 23-gauge syringe needles. A sterile
1-cm x 0.6 mm diameter stainless steel Kirschner wire was coated with the appropriate PC
mixture (n = 3/group) and inserted into the femur. The wound was inoculated with
approximately 104 colony-forming units of UAMS-1 and closed. The animals were humanely
euthanized after 1 week, at which time the wire implant and appropriate femur were removed to
determine the number of viable bacterial CFUs on/in each. The quantity of attached bacterial
colonies on wire implants was determined by sonicating and vortexing in sterile PBS, plating the
PBS on agarose, and counting the number of colonies after overnight incubation at 37° C. The
surrounding bone was homogenized and suspended in sterile PBS. The number of viable
bacterial colonies in the bone was then counted by plating the homogenized solution on agarose,
incubating overnight and counting the number of bacterial colonies, similar to the process used
for the wire implants. Bacterial clearance for an implant or bone was defined as a viable
bacterial CFU count of zero.
SigmaPlot (Systat Software, Inc, San Jose, CA, USA) was used for all statistical analysis
testing. Kruskal Wallis Analysis of variance (ANOVA) on ranks was used to test for differences
in bacterial counts for each group, including control, the implants and the surrounding tissue.
Dunn’s multiple comparison test vs controls was used for post hoc analysis. Fisher’s exact test
was used to test for differences in the proportion of complete bacterial clearance between nonantimicrobial control coatings and combined results of antimicrobial coatings. A significance
level of 5% was used for determining statistical significance between groups.
Results
The PC-coated coupons eluted C2DA and amikacin in a burst pattern over the first 1 to 2
days that tapered off by Day 3 (Fig. 9A). Amikacin elution stopped after Day 3 in most groups,
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but there was an increase in elution at Days 6 and 7 in some groups (Fig. 9B). C2DA eluted at a
faster rate in coatings containing 15% or 25% wt. amikacin. It is worth noting that only 48% of
the incorporated C2DA and 57% of incorporated amikacin were recovered from the eluate
samples.

Fig. 9A–B Graphs show elution profiles for (A) C2DA and (B) amikacin from
phosphatidylcholine coatings with 15% wt C2DA (mean ± SD).

The presence of C2DA in the eluate lowered the amount of amikacin required to inhibit
UAMS-1 growth; an eluate with no C2DA and 156 µg/mL amikacin was unable to inhibit
UAMS-1 growth, but a sample with 19 µg/mL amikacin and 88 µg/mL C2DA was inhibitory
(Table 8). The eluates from coatings containing 5% wt. amikacin did not inhibit UAMS-1
regardless of C2DA, and eluates from coatings with 15% amikacin and no C2DA were also
uninhibitory. However, all eluates from coatings containing either 25% amikacin or 15%
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amikacin and any concentration of C2DA were able to inhibit UAMS-1. All tested eluates were
effective against PA-ATCC 27317.

No attached bacterial colonies were detected on the wire implants from antimicrobialloaded PC groups, which is lower than colonies found on coatings only (Fig. 10A). The
proportion of implant clearance was different between antimicrobial-loaded groups and unloaded
PC (coating only: 1/3; amikacin: 3/3; C2DA: 3/3; C2DA + amikacin: 3/3; p = 0.045). The
proportion of bone clearance was also higher between all antimicrobial-loaded groups and
coating alone (coating only: 0/3; amikacin: 3/3; C2DA; 3/3; C2DA+Amkikacin: 1/3; p = 0.03).
There were differences in CFU counts on implants between the treatment groups and controls,
though not statistically different at the p < 0.05 significance level using Kruskal Wallis ANOVA
(p = 0.088). All nonloaded coatings had viable colony-forming units of bacteria in the
surrounding bone (Fig. 10B). Kruskal Wallis ANOVA detected a statistically significant
difference in bacterial counts from the surrounding bone (p = 0.033), and the amikacin alone and
C2DA alone groups contained significantly less bacteria than the control group (p = 0.035). The
C2DA and amikacin combination coating did not produce a significant reduction in bacterial
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count based off of ranked testing (p = 0.620; CFU count: coating only: 1.6 * 106 ± 2*106 ;
amikacin: 0 ± 0; C2DA: 0 ± 0; C2DA + amikacin: 8200 ± 1*104 CFUs).

Fig. 10A–B Scatterplots show the number of viable bacterial CFUs recovered from (A) wire
implants and (B) surrounding bone tissue (mean ± SD).

Discussion
Local antibiotic delivery devices offer an effective method to achieve high local
antibiotic concentrations at surgical sites for prophylactic treatment of biofilm-based PJI.
Bacterial adhesion is often cited as the critical event in the establishment of biofilm on implant
surfaces [2], making this process a potential target for future infection prevention strategies. The
biofilm inhibitor C2DA has been previously shown to induce dispersion of mature biofilms,
inhibit the formation of new biofilms from cultures of planktonic bacteria, inhibit bacterial
growth at higher concentrations, and exert synergistic activity with common antibiotics. These
properties suggest that C2DA may be able to inhibit biofilm formation on implants if delivered
alongside antibiotics at the surgical site. There is a current gap in research between promising in
vitro studies and the development of effective local drug delivery devices to administer them at a
surgical wound bed. PC, a biocompatible and biodegradable phospholipid, may be used to
incorporate various antimicrobials and applied to implant surfaces for local drug delivery. PC is
37

advantageous for prophylactic implant protection because it rapidly degrades, can deliver a wide
variety of drugs without the harsh loading or preparation steps seen in PMMA polymerization,
and, as a coating, provides better implant coverage compared to collagen sponges that must rely
on diffusion to deliver antimicrobials to the implant surface [19, 27]. This work suggests that
phosphatidylcholine coatings can effectively release amikacin and C2DA for 2-3 days from
orthopedic implants to prevent bacterial colonization. From a clinical perspective, these coatings
have potential for prophylactic treatment of PJI.
Although the amikacin and C2DA-loaded PC coatings show promise in the animal
model, there are some limitations with this study. The elution study method shows the drug
elution pattern for our system but is not a fair representation of the various processes occurring in
vivo, in which the degradation rate may be different. The animal model was only a pilot study
with three animals per group and limited controls, making it impossible to draw firm conclusions
about the effectiveness of the coating or local delivery of C2DA. The results of the in vitro
turbidity assay and the in vivo bacterial counts are conflicting, with combinations of C2DA and
amikacin performing better in vitro while the combination group was the only treatment group to
test positive for bacteria in the surrounding bone in vivo. Due to the preliminary nature of this
study and limited sample size it is inappropriate to make comparisons between the antibiotic,
C2DA and combination coatings; however, statistical analysis does suggest that drug loaded
coatings were significantly better than the PC only control. It is currently unknown how well
these coatings will withstand aggressive implantation procedures or how coating will influence
host-implant interactions, so these results may not translate into human studies. While limited,
the results do provide pilot data to support and plan further extended preclinical studies regarding
the effectiveness of PC coatings and C2DA. It should also be noted that this coating is meant to
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rapidly degrade, and will offer no protection from hematogenous seeding of bacteria from distant
infections after it has degraded.
Elution study results suggest that PC coatings can elute amikacin and C2DA over several
days with a rapid burst pattern over the first 2 days that quickly tapers off. The rapid burst of
antibiotic will ensure high concentrations of antibiotic in the wound bed, and incorporation of
C2DA may delay bacterial attachment long enough for antibiotics or the innate immune system
to kill any invading bacteria. This burst release does, however, remove most of the drug payload
quickly and shortens the overall effective elution period. The burst release also increases the
chances of achieving cytotoxic levels of antimicrobials during the first day and therefore limits
the amount of drug that may be incorporated. Interestingly, high-performance liquid
chromatographic analysis shows only half of the incorporated antimicrobials were recovered in
the eluate samples. This is likely related to bulk erosion of PC from the implant coating [10]. We
believe that, during the initial elution period, large chunks of PC will erode from the coating and
become dispersed in the PBS media as liposomes with encased C2DA and amikacin. These
liposomes were removed when the media was changed daily, and the antimicrobials were not
detected by the high-performance liquid chromatography because they were still encased in PC.
This is advantageous because the liposomes will remain in the wound bed and continue to elute
antimicrobials as the PC hydrolyzes and degrades, further extending the elution pattern beyond
what was determined by high-performance liquid chromatography. During elution of amikacin, a
second burst release was observed for the 5% amikacin group at Days 6 and 7, which has been
seen in previous antibiotic elution studies using PC [7]. It was previously suggested that this is
related to PC hydrolysis; however, additional research is needed to understand why this
phenomenon was not observed in groups with higher antibiotic loading concentrations.
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C2DA has also shown synergistic effects with many common antibiotics and will lower
the amount of drug needed to kill bacteria [18, 21], which is reflected in the results of our
turbidity testing. Coatings loaded with only 15% amikacin were unable to inhibit UAMS-1
growth; however, eluates from coatings with 15% amikacin and C2DA were inhibitory. This
supports previous findings showing combinatorial effects between amikacin and C2DA.
Coatings with 5% amikacin were unable to inhibit UAMS-1 growth regardless of the presence of
C2DA, suggesting that this level of loading is too low for clinical use. All tested samples were
able to inhibit PA-ATCC 27317, regardless of the presence of C2DA. S aureus and P aeruginosa
are the most common Gram-positive and Gram-negative pathogens present in orthopaedic
infections, respectively [1, 8, 26], suggesting that local C2DA and amikacin release can provide
broad spectrum protection against a variety of potential pathogens.
The in vitro findings are in accordance with the findings of our pilot animal study, in
which all treatment groups were able to prevent bacterial attachment to the wire implant during
the 1-week study. Although previous research shows that 500 µg/mL C2DA is required to inhibit
bacterial growth [14, 23], the C2DA-only coating was able to completely inhibit bacteria on the
wire implant and in the surrounding bone. In vitro elution data suggest that the peak C2DA
concentration should be approximately 100 µg/mL or 20% of the minimum inhibitory
concentration. One possible explanation for the complete clearance of bacteria on the wire
implant and in the bone tissue is that the presence of C2DA delayed bacterial attachment long
enough for the murine innate immune system to respond. This finding does call into question the
use of antibiotics, since the fatty acid was able to achieve complete bacterial clearance on the pin
and in the surrounding bone. Turbidity testing with the eluate samples still suggests that there is
a combinatorial or synergistic effect between amikacin and C2DA, and the limited sample size of

40

the in vivo groups limits the validity of any observations between treatment groups. However,
this finding was not expected, and does warrant an additional in vivo study with increased sample
sizes to provide more statistically relevant data. The presence of bacteria in the surrounding
bone of a limited number of animals suggest that the distance of antibiotic elution may be limited
to the tissue adjacent to the implant. Although the number of colony-forming units recovered
from bone tissue in the combination group was lower than that of the controls, bacteria could
rebound and cause infection. Nevertheless, the antimicrobial-loaded coatings were able to
increase the proportion of bacterial clearance when compared with the control. Because this
coating would likely be an adjunct preventive measure to systemic prophylactic antibiotics [20],
this risk of infection in surrounding tissue will be minimized.
In conclusion, phosphatidylcholine coatings can be used as local drug delivery devices
for prevention of bacterial colonization on implant surfaces. The high early antimicrobial elution,
as seen with in vitro elution studies, kills any contaminating bacteria during the initial wound
healing time period. Local delivery of C2DA may prevent bacterial attachment and increase
antibiotic effectiveness, preventing colonization and formation of biofilm. Our pilot in vivo
murine study supports these findings and warrants testing with more antibiotics, animal studies
with larger sample sizes and additional controls, and improved methods of clinical application of
coatings to implants.
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CHAPTER 4
Discussion
The purpose of this study was to evaluate the use of a phospholipid coating for dual
delivery of antibiotics and a biofilm inhibitor as a prophylactic measure against PJI. PJIs are a
major financial burden on the health care system and significantly decrease patient quality of life
secondary to pain, physical limitations, and repeat hospitalizations [14, 27, 64]. Infectious
bacteria attach to the implant surface, excreting an extracellular matrix of polysaccharides and
proteins that protects the cells from immune response [12]. This phenotypic switch to this
biofilm mode of growth is accompanied by an increased tolerance to antibiotics and
antimicrobials, with common antibiotics showing up to 1000-5000x higher minimum inhibitory
concentrations (MIC) against orthopedic pathogens once they form biofilm [57, 62]. Treatment
becomes further complicated by the presence of persister cells that remain metabollically
inactive, and therefore more difficult to treat with antibiotics, until widespread death or damage
occurs within the biofilm, at which time they revert to a proliferative state and repopulate the
biofilm [38, 39].
As many as 66% of PJIs are caused by bacteria that contaminate the wound during the
implantation procedure [4, 21]. Local drug delivery has been used successfully as an adjunct to
systemic antiboitic therapy as a prophylactic measure against this contamination; however,
infection rates still range between 1-2% for primary arthroplasty and 5-40% for revision
arthroplasty [14, 56, 62]. A biofilm inhibitor, C2DA, was selected as a potential new prophylatic
agent due to its ability to prevent bacterial attachment and the formation of biofilm communities
[15, 41], thereby leaving the bacteria in the planktonic form that is much easier to treat. Previous
research has shown nanomolar concentrations of C2DA to upregulate the expression of genes
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involved with metabolism and proliferation, encouraging the cells to multiply rather than enter
the slow-growth biofilm phenotype [46]. This finding suggests that local delivery of C2DA at
the implantation site would slow or prevent bacterial attachment to the implant surface, thereby
increasing the effectiveness of antibiotics delivered at the wound site.
C2DA is a hydrophobic short chain fatty acid, in contrast to water soluble antibiotic
typically used in local drug delivery. The amphipahtic phospholipid PtC was chosen as a carrier
matrix due to the ease with which it can be loaded with both types of molecules. At body
temperature, PtC is in an adhesive gel-phase [26] that can be applied to surfaces as a thin coating
by gently wiping the gel across the surface. This coating could be applied to the implant before
being placed in the patient, therby offering protection before implantation. Other forms of
prophylactic local drug delivery, such as PMMA beads or spacers, caclium sulfate beads and
chitosan sponges, rely on diffusion after the implant is placed to spread antibiotics throuhout the
implant site, offreing a potential gap in protection [45, 59]. Other coatings, such as chitosan, solgel or covalently bound vancomycin, must be fabricated and processed with the implant [1, 3,
24]. PtC coatings are advantagous in that they can be loaded with case specific antibiotics at the
time of surgery and applied in the operating room, giving clinicians more flexibility with drug
choice and loading concentration.
Elution studies with ciprofloxacin confirm that the PtC coating is still present and capable
of releasing its drug payload at up to 9 days in aqueous media. The steady elution of
ciprofloxacin seen in vitro is desirable in that higher levels of antibiotic are maintianed after day
4, compared to amikacin, tetracycline, ceftazidime, levofloxacin and vancomycin. These
antibiotics showed a large burst release on day 1 that depleated the drug payload, and elution
slowed to low levels by days 3-4. This burst release may be reduced in vivo, as previous studies
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have shown that PMMA release in vitro is often higher than actual release in vivo due to drug
saturation in nearby tissue [36], as opposed to daily refreshment common in elution studies.
C2DA was shown to follow a first order elution pattern as well, with high levels of antibiotic on
day 1 and continued low level elution throughout day 7. Up to the maximum 15% wt. loading
concentration used here, the increased proportion of C2DA to PtC carrier did not seem to alter
the drug elution profile, and C2DA elution was higher for the 15% wt. group than groups with
lower loading concentrations at all time points.
Bacterial turbidty testing with eluate samples confirms the activity of antibiotics released
from the PtC coatings. Samples with C2DA alone were not inhibitory, which was expected as
previous literature has reported the MIC against S. aureus and P. aeruginosa at twice the levels
achieved in this study [44]. Groups containing ciprofloxacin performed the best in this study due
to the high concentrations eluted at later time points, with the 15% ciprofloxacin, 15% C2DA
group inhibiting growth and biofilm formation of both strains at all time points. Amikacin was
the only antibiotic to show synergistic effects with C2DA during this study (Chapter 3), and
these effects were only seen in a few samples. This synergy appears to be the result of increased
bacterial membrane permeability caused by C2DA, which is more pronounced at higher ( ≥ 100
µg/ml) concentrations of C2DA [44]. These concentrations were only reached durign the first 12 days of elution, at which time tetracycline, ceftazidime, ciprofloxacin, and vancomycin were
still eluting at high concentrations, thereby masking any synergistic effects. Since coatings with
only 5% C2DA still eluted the nanomolar concentrations required to induce bacterial dispersion
up to day 7, in the context of these results, it seems likely that coatings containing 15% antibiotic
and 5% C2DA would perform as well as coatings with 15% antibiotic and 15% C2DA. The
synergistic effects would still be beneficial if coatings with 15% C2DA only were used as an
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adjunct to systemic therapy since the concentrations possible by IV are much lower than the
amounts delivered locally in this study.
C2DA induced only mild biofilm inhibition in this study, highlighting a limitation of
microplate bacterial testing. Most studies on C2DA have been performed using mature biofilms
or continuous flow bioreactors which allow for constant exchange of media. In this test, large
quantities of bacteria were introduced to a small volume of fixed media along with a known
promotor of proliferation, C2DA. The high number of cells, coupled with limited nutrients and
absence of antibiotics, may have produced conditions that promoted the formation of biofilm,
negating the inhibitory effects of the C2DA. In a clinical setting, at minimum, systemic
antibiotics would be present at the implant site to help kill any planktonic bacteria. Continuous
flow bioreactors and in vivo models of PJI would overcome these limitations of static assays and
provide improved insight into the efficacy of the C2DA.
MC-3T3 osteoblast cellular proliferation in the presence of PtC coatings was nearly
identical to that of cells exposed to uncoated titanium, indicating that they caused little to no
effect on osteoblast growth. Coatings with C2DA did not cause a statistical drop in viability at
day 1 or 3, supporting previous findings that C2DA was cytocompatible with osteoblasts up to
concentrations of 500 µg/ml [49]. Coatings with 15% C2DA and 15% vancomycin, tetracycline
or amikacin did cause a significant drop in proliferation, likely as a result of the combined
cytotoxic stress of moderate doses of antibiotic and C2DA [48, 49]. While the decrease in
proliferation for samples receiving 15% ciprofloxacin, 15% C2DA was not statistically
significant, the decrease was slightly more than the 30% cutoff recommended by ISO 10993-5
for medical devices. These results could be improved by lowering drug level concentrations,
thereby reducing the amount of cytotoxic stress induced by the coatings. Reducing C2DA
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content to 5% would likely improve the cytocompatibility scores of the coatings to acceptable
values while still retaining biofilm inhibiting properties for up to 7 days.
Results of the in vivo murine model of orthopedic implant infection are promising. The
absence of viable bacteria in mice receiving the C2DA only coating was unexpected as no
systemic antibiotics were given for this study. Possible explanations include higher than
expected in vivo concentrations of C2DA, as described above, or that the bacteria was unable to
attach to the implant and therefore cleared by macrophages. Mice receiving coatings 5%
amikacin only were also free of bacteria, although there was a small amount of viable bacteria
present in the surrounding bone of 2 mice that received the coatings with 5% amikacin 10%
C2DA. Given the small sample sizes used in this pilot study it is difficult to draw conclusions,
and despite a small quantity of bacteria in the bone, no bacteria were recovered from the wire
implants of mice that received the coating containing C2DA and antibiotic. Further studies with
larger sample sizes will be needed to expand upon these results.
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CHAPTER 5
Conclusions
Biofilm based orthopedic infections are a major healthcare concern, both in terms of
financial cost and patient morbidity. The body of this work supports the incorporation of both
antibiotics and cis-2-decenoic acid (C2DA), a recently identified biofilm inhibitor, into
phosphatidylcholine (PtC) coatings for application on orthopedic implants. Local delivery of a
biofilm inhibitor is novel and may further reduce current infection rates of 1-2% for primary
arthroplasty and 5-40% for revision arthroplasty.
In vitro elution and biofilm studies show that PtC coatings can release active
concentrations of C2DA antibiotics for 4-9 days, depending on the antibiotic choice. Previously
reported findings of synergy between antibiotics and C2DA were not seen in many of the
coatings because the high loading concentration of antibiotics masked these effects until C2DA
elution rate had already fallen below the required levels. A pilot in vivo murine model of
orthopedic infection supported the efficacy of the coatings, with all antibiotic and/or C2DA
loaded coatings clearing implant of infection. In vitro cytocompatibility studies suggest that the
coating itself has no effect on cellular proliferation, although C2DA loading concentrations may
need to be reduced in coatings that contain both the C2DA and antibiotics.
In conclusion, the results of these studies support the hypothesis that PtC can release
active concentrations of antibiotics and C2DA from implant materials. PtC showed no signs of
cytotoxicity and can be loaded with multiple antibiotics, suggesting that it is an appropriate
material for 3-7 day prophylactic delivery of antibiotics to protect against early or delayed PJI.
Future work will be needed to fully assess the effects of the C2DA but preliminary in vivo
support our hypothesis.
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Chapter 6
Recommendations for Future Work
These studies have confirmed that PtC can release high concentrations of active
antibiotics; however, the extent of biofilm inhibition by C2DA has not yet been effectively
quantified. Coating effectiveness should be evaluated using continuous flow bioreactors and, if
funding permits, larger animal models. Rabbit or goat models of PJI would provide more insight
into clinical efficacy as larger, more relevant implants could be used and histological staining of
surrounding tissue would provide insight into host immune response to the coating. As noted in
Chapter 2, coating mass varied between groups and makes it difficult to compare results at
various loading concentrations. Current work has shown that PtC coatings can be aerosolized
and sprayed onto metal surfaces; this work should be extended to include antibiotics and C2DA
if possible, which would result in more homogeneous coatings, make the application process
easier, especially in a surgical setting, and decrease variability between samples.
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APPENDIX A: AGAROSE OVERLAY ASSAY
Rationale
The agarose overlay test is a qualitative indirect contact assay for cytocompatability. As
outlined by ISO 10993-5, cytocompatability is determined by cell deformation and/or death
around the sample, with each sample classified by reactivity: none, slight, mild, moderate or
severe. This test assesses the effects of leachables from PtC coatings, including antibiotics,
C2DA, phosphatidylcholine, and phostaphidylcholine degradation products.
Methods
MC-3T3 osteoblasts were grown in Dulbecco's Modified Eagle Medium w/ High Glucose
supplemented with 10% Fetal Bovine Serum and 100 µg/mL Normocin™ antimicrobial reagent
(InvivoGen, San Diego, CA). The cells were seeded onto 6 well plates at a density of 1*105
cells/cm2 and allowed to attach overnight. A 2% agar solution was mixed in phosphate buffered
saline, autoclaved at 121° C for 21 minutes and kept at 50° C until use to prevent gelling. The
cell media was aspirated and replaced with a mixture of agar solution and supplemented media at
a ratio of 1:1. Cells were allowed to incubate 30 minutes as the agar solidified. A 100 µg/ml
neutral red solution was added on top of the agar and allowed to sit for 30 minutes, after which it
was aspirated. Cp-titanium coupons (1 cm diameter x 2 mm thickness) were coated with
phosphatidylcholine containing no additives, 5% C2DA, 10% C2DA, 15% C2DA, 15%
vancomycin and 15% C2DA, 15% tetracycline and 15% C2DA, 15% amikacin and 15% C2DA,
15% ceftazidime and 15% C2DA, or 15% ciprofloxacin and 15% C2DA (n = 3). Uncoated
titanium was used as a negative control and brass was used as a positive control. These samples
were placed directly on top of the agar in the center of each well and allowed to incubate
overnight. Images of each sample were taken at 4x magnification (Eclipse TE300, Nikon

58

Corporattion, Tokyo, Japan) and pieced together with Bioquant software (BIOQUANT Image
Analysis Corporation, Nashville, TN).
Results
Cells were classified as living if they contained the neutral red dye. The following
groups did not cause any cell death or damage around the samples: uncoated titanium, PtC, 5%
C2DA, 10% C2DA, 15% C2DA. All of the groups containing antibiotics and C2DA caused
some cell death in the area between 1-5 mm from the sample (Fig. 11-12). None of the coating
samples disturbed cells 1 cm or more from the sample.
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Discussion
ISO 10993-5 sets the following criteria for determining cytotoxicity with the agarose
overlay: No reactivity-no detectable zone around or under specimen; slight reactivity: some
malformed or degenerated cells under specimen; mild reactivity-zone limited to area under the
specimen; moderate: zone extending specimen size up to 1 cm; severe: zone extending farther
than 1 cm beyond specimen. Moderate and severe reactivity are considered cytotoxic effects.
Due to the mass of the titanium coupons and thin agar layer used in this study, it was deemed
inappropriate to distinguish between no, slight and mild reactivity, and rather distinguish
61

between cytocompatible or cytotoxic, using the criteria defined above. The findings of the
agarose overlay study are in agreement with the Chapter 2 cellular viability results, which
showed that PtC by itself and loaded with up to 15% C2DA was cytocompatible, however
mixtures with 15% C2DA and 15% antibiotic were slightly below the cutoff value that defined
cytotoxicity.
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APPENDIX B: CELLULAR ATTACHMENT ASSAY
Rationale
Cellular attachment is an important process in cell-communication and wound healing.
Materials or treatments that disrupt cell attachment may alter the inflammatory and/or healing
processes, thereby changing the way the body interacts with a medical implant. The purpose of
this study is to determine what effects, if any, PtC coatings have on cellular attachment to
titanium samples.
Methods
MC-3T3 osteoblasts were grown in Dulbecco's Modified Eagle Medium w/ High Glucose
supplemented with 10% Fetal Bovine Serum and 100 µg/mL Normocin™ antimicrobial reagent
(InvivoGen, San Diego, CA). Cp-titanium coupons (0.75 in diameter x 0.1 in thickness) were
coated with phosphatidylcholine containing no additives, 15% C2DA, or 15% C2DA and 15%
ciprofloxacin and added to 12 well plates with a well diameter of approximately 0.85 in. (n=3).
Uncoated coupons were used as a control. The MC-3T3 cells were seeded directly on top of the
samples at a density of 1*105 cells/cm2, and the samples were incubated for 5 hours. After
incubation, the media was removed and stored in separate containers. Two washes with PBS
were performed by gently adding 0.5 mL PBS to each sample, removing the PBS and adding it
to the sample media, and repeating. Cellular attachment was determined by measuring the
number of cells in the aspirated media-PBS mixture and subtracting from the number of seeded
cells. One sample from each group received Live/Dead stain (Invitrogen, Thermo Fisher
Scientific, Carlsbad, CA) with 6 µM calcien AM and 12 µM ethdium homodimer-1, and was
incubated for 30 minutes. Samples were then imaged at 4x magnification (Eclipse TE300, Nikon
Corporation, Tokyo, Japan) with a Nikon 100W super high pressure mercury lamp and pieced
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together with Bioquant software (BIOQUANT Image Analysis Corporation, Nashville, TN).
One way ANOVA was used to test for differences in the number of attached cells, with HolmsSidak post hoc and a level of significance α = 0.05.
Results
Approximately 10x more cells were recovered from coated samples vs uncoated controls
(p < 0.001, Fig. 13), with more than half of the deposited cells failing to attach to the coated
samples.

Live/Dead staining supports these findings (Fig. 14). There is an even distribution of cells at
high density across the uncoated titanium sample, with little difference in cell distribution
between the metal coupon and surrounding tissue culture plastic. Samples that were coated with
phosphatidylcholine appear to have fewer cells attached and the distribution is uneven, with
much higher concentrations of cells seen in the surrounding tissue culture plastic. Few dead cells
can be seen in any of the samples.
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Discussion
The phosphatidylcholine coatings appears to slow cellular attachment to the metal
surface. While the number of attached cells for coated samples was significantly less compared
to uncoated controls, Live/Dead staining shows that some cells were able to attach to the coated
metal, suggesting that attachment was not completely inhibited. Since cellular attachment
appears to be significantly reduced onto PtC coated surfaces, the decrease in cellular
proliferation seen in Chapter 2 may be partially caused by a decrease in effective growth area as
the cells cannot attach and grow as effectively on the coating. The fatty acid tails of the PtC may
be creating a hydrophobic surface on the metal, reducing cell affinity for the surface; however,
this will need to be assessed with further testing such as the water contact angle assay.
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The initial decrease in attachment may not be relevant for slow growing tissue like bone,
as the phosphatidylcholine would degrade rapidly and has been shown to promote bone ingrowth
in other applications [29]. The decrease in attachment may due to a decrease in protein binding
to the coated surface; animal models with appropriate histology will be required to determine if
this has an effect on the inflammatory response and wound healing.
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APPENDIX C: SUBSTRATE EFFECT ON ELUTION
Rationale
Medical devices, including hip and knee implants, are constructed of a wide variety of
materials, including metals, ceramics, and polymers. The purpose of this study is to test drug
release from phosphatidylcholine coatings applied to various materials to determine if material
choice effects the release rates.
Methods
Phosphatidylcholine coatings containing 15% C2DA and 15% ciprofloxacin were applied
to 1x3 in2 cp-titanium, 316 stainless steel, ultra-high molecular weight polyethylene
(UHMWPE), and porous hydroxyapatite samples (n=3). Mass was adjusted to 9 ± 1 mg and
each sample was placed in a petri dish with 10 mL PBS. Media was exchanged daily for 7 days,
and the concentration of C2DA and ciprofloxacin in each sample was determined by HPLC.
Two way ANOVA with Holms-Sidak post hoc was used to test for significant differences in
elution between each sample with a level of significance α = 0.05.
Results
There was no difference in C2DA release from coatings applied to different materials (p
> 0.5, Fig. 15A). C2DA eluted in a burst response over the first 24 hours and stopped eluting by
day 4. Coatings applied to porous hydroxyapatite eluted at higher amounts on day 2 (p < 0.001);
however, there were no other significant differences in ciprofloxacin elution between samples
(Fig. 15B).
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Discussion
Both C2DA and ciprofloxacin release dropped faster in this study than in Chapter 2 as a
result of the higher elution media to coating mass ratio. Coatings applied to the hydroxyapatite
samples were thicker as a result of the porous nature of the surface, which effectively trapped
more PtC within the pores, and the coating only had to be applied to approximately 25% of the
sample to achieve the same mass as the other groups. The extra thickness of this coating may
account for the increase in ciprofloxacin elution. Elution was nearly identical from titanium,
stainless steel, and UHMWPE, suggesting that the base material does not affect elution rate,
however the surface finish and porosity will affect coating thickness and mass. Porous or rough
surfaces will entrap more of the phosphatidylcholine, indicating that drug loading concentrations
may need to be reduced compared to coatings applied to smooth surfaces in order to maintain
desired elution concentrations.
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APPENDIX D: EFFECT OF GAMMA STERILIZATION ON
PHOSPHATIDYLCHOLINE AND CIS-2-DECENOIC ACID
Rationale
Medical devices must be sterilized prior to use in order to prevent infection. The high
temperatures achieved by an autoclave are unsuitable for phosphatidylcholine, which undergoes
a phase transformation at 60° C. Gases may not be able to penetrate into the center of large
phosphatidylcholine pieces, ruling out gas sterilization methods such as ethylene oxide. Gamma
rays are easily capable of penetrating materials such as phosphatidylcholine and reliably
destroying any contaminating pathogens. This study tests the effects of gamma radiation on
C2DA and the elution properties of phosphatidylcholine.
Methods
C2DA, plain phosphatidylcholine, and a mixture of phosphatidylcholine with 15%
ciprofloxacin and 15% C2DA were subjected to low dose gamma sterilization (25.0 to 40.0 kGy
dosage). Nuclear magnetic resonance (NMR) spectroscopy was performed on non-sterilized and
gamma sterilized C2DA samples by the Department of Chemistry at the University of Memphis.
Cp-titanium coupons (1 cm diameter x 0.2 mm thickness) were then coated with either the
gamma sterilized 15% C2DA 15% ciprofloxacin mixture, gamma sterilized PtC that had been
mixed with nonsterile 15% C2DA and 15% ciprofloxacin, and nonsterile PtC mixed with
nonsterile 15% C2DA and 15% ciprofloxacin (n=3). Coating mass was adjusted to 7.5 ± 0.5 mg
to prevent differences in coating mass from affecting study results. Samples were placed in 12
well plates lined with 41 µm nylon filters (Merck Millipore, Billerica, MA, USA) and filled with
1 mL PBS. Samples were taken daily with complete media refreshment for 7 days. C2DA and
ciprofloxacin concentrations in each sample were determined by HPLC. Two way ANOVA with
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Holms-Sidak post hoc was used to test for differences in daily elution with level of significance
α = 0.05. Eluate samples from gamma sterilized and nonsterile coatings were diluted 1 in 10
with tryptic soy broth containing either S. aureus or P. aeruginosa. Samples were incubated
overnight and visually assessed the next day for bacterial growth.
Results
NRM spectroscopy confirms that C2DA was intact after gamma sterilization, with no
abnormal or unexpected peaks present (Fig. 16).

There were no statistical differences in C2DA elution from any of the coatings; however,
ciprofloxacin elution from the nonsterile coating was higher than elution from coatings with
gamma sterilized PtC after day 3, with differences becoming significant by day 7 (p < 0.05, Fig.
17).
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Turbidity testing results are shown in Table 9, with minus signs indicating that all samples
inhibited bacterial growth, and each plus sign representing a sample that did not inhibit bacterial
growth. All samples were inhibitory except for one sample from the gamma sterilized group on
day 7.
Table 9: Turbidity testing with gamma sterilized coating eluates

Discussion
Based on NMR spectroscopy, C2DA is able to withstand gamma sterilization without significant
degradation. The decrease in elution seen at later time points from coatings containing gamma
sterilized PtC may be caused by gamma radiation induced hydrolysis of the ester bonds within
the PtC, causing it to degrade more rapidly. However, the gamma sterilized coatings were still
able to elute an average of over 50 µg/ml ciprofloxacin throughout the study, demonstrating that
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they are still capable of eluting active concentrations of antibiotic for 1 week. The slight
decrease in elution at later time points is acceptable given the need for a suitable sterilization
process. Turbidity results confirm that antibacterial properties of the coating were still intact
after sterilization.
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